Literature DB >> 7564500

A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review.

D Macdonald1, R C Aguiar, P J Mason, J M Goldman, N C Cross.   

Abstract

Chromosomal breakpoints associated with malignancy are known to cluster at particular regions of the karyotype. Based on a review of the literature we have identified a novel leukaemia syndrome associated with translocations involving 8p11. This syndrome is distinct from the previously described translocation t(8;16)(p11;p13) associated with acute monoblastic leukaemia. We have summarized the clinical and cytogenetic features of 13 case reports which describe a myeloproliferative syndrome with eosinophilia, lymphadenopathy and a high incidence of T cell non-Hodgkin's lymphoma with progression to acute myeloid leukaemia. The translocations involving 8p11 were: either t(8;13)(p11-12;q11-12), t(8;9) (p11;q32-34) or t(6;8)(q27;p12). In two cases of t(8;13) molecular studies have mapped the chromosome 13 breakpoint to a 1.5 Mbp region, but a full molecular characterization of these translocations is required. In view of the striking clinicopathological and karyotypic similarities between these cases we propose that they be considered a single nosological entity and termed '8p11 myeloproliferative syndrome'.

Entities:  

Mesh:

Year:  1995        PMID: 7564500

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  17 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

Review 2.  An alternative approach to medical genetics based on modern evolutionary biology. Part 4: HERVs in cancer.

Authors:  Frank P Ryan
Journal:  J R Soc Med       Date:  2009-11       Impact factor: 5.344

3.  Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.

Authors:  Yadan Wang; Xiaofei Wu; Jun Deng; Hao Yu; Ren Xu; Zhiyi Zhu; Shichun Tu; Yu Hu
Journal:  Cancer Biol Ther       Date:  2016-08-02       Impact factor: 4.742

4.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).

Authors:  C Popovici; J Adélaïde; V Ollendorff; M Chaffanet; G Guasch; M Jacrot; D Leroux; D Birnbaum; M J Pébusque
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

5.  Fine-needle aspiration cytology of T-lymphoblastic lymphoma associated FGFR1 rearrangement myeloproliferative neoplasm.

Authors:  Rishi A Patel; Andrea M Sheehan; Christie J Finch; Dolores Lopez-Terrada; Vivian S Hernandez; Choladda V Curry
Journal:  Diagn Cytopathol       Date:  2013-08-01       Impact factor: 1.582

6.  A novel chromosomal abnormality, t(6;10)(q27;q22), found in a polycythemic potential donor for allogeneic hematopoietic stem cell transplantation.

Authors:  Hideki Mitsui; Norimitsu Saito; Atsushi Satake; Tsuyoshi Nakazawa; Takahiro Karasuno; Akira Hiraoka
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

7.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

8.  The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report.

Authors:  Ami Goradia; Michael Bayerl; Dennis Cornfield
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

9.  Dysregulated signaling pathways in the development of CNTRL-FGFR1-induced myeloid and lymphoid malignancies associated with FGFR1 in human and mouse models.

Authors:  Mingqiang Ren; Haiyan Qin; Eiko Kitamura; John K Cowell
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

Review 10.  Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Hyeyoung Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Byung-Sik Cho; Hee-Je Kim
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.